InsiderTrades

Form 4 for HOWL Werewolf Therapeutics, Inc.

Accepted 2025-05-14 00:00:00 ET · period of report 2025-05-12 · accession 0001415889-25-012942 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
MI 2025-05-14 2025-05-12+ HOWL RA Capital Nexus Fund II, L.P. Dir, 10% P - Purchase $0.9082 +536.4K 6.02M +10% +$487.2K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-05-13 P A 52,974 $0.98 6,074,943 I See footnotes — — (F4) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.96 to $0.99 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. (F3) RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. (F2) Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
2 Common Common Stock 2025-05-14 P A 162,539 $0.98 6,237,482 I See footnotes — — (F5) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.96 to $0.99 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. (F3) RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. (F2) Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
3 Common Common Stock 2025-05-12 P A 320,913 $0.86 6,021,969 I See footnotes — — (F1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.82 to $0.89 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. (F3) RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. (F2) Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").